Abstract
随着医疗技术的不断进步，小出生胎龄极限早产儿救治成功率逐年提高，极早或超早产儿氢化可的松的临床应用呈增多趋势。本文综述氢化可的松在极早或超早产儿中的使用时机、剂量及其与地塞米松的对比，探讨其对极早或超早产儿临床结局的影响。临床应用氢化可的松需权衡利弊风险，慎重选择使用时机和剂量。.
MeSH terms
-
Anti-Inflammatory Agents / administration & dosage
-
Anti-Inflammatory Agents / therapeutic use
-
Dexamethasone* / administration & dosage
-
Dexamethasone* / therapeutic use
-
Gestational Age
-
Glucocorticoids / administration & dosage
-
Glucocorticoids / therapeutic use
-
Humans
-
Hydrocortisone* / administration & dosage
-
Hydrocortisone* / therapeutic use
-
Infant, Extremely Premature*
-
Infant, Newborn
-
Infant, Premature*
-
Infant, Premature, Diseases / drug therapy
-
Treatment Outcome
Substances
-
Hydrocortisone
-
Dexamethasone
-
Anti-Inflammatory Agents
-
Glucocorticoids